Research Article

Pyruvate Kinase Deficiency along with Detection of Plasminogen Activator Inhibitor (PAI-1) 4G/4G Homozygous Genotype in Pregnancy

Authors

Stamatia Theodoridou¹, Leonidas Zepiridis², Alexandra Agapidou³, Theodoros Theodoridis⁴ and Timoleon - Achilleas Vyzantiadis⁵

¹,³Hemoglobinopathy Prevention Unit, Thessaloniki, Greece

²,⁴First Obstetric and Gynecological Department, Aristotle University of Thessaloniki, Greece

⁵First Department of Microbiology, Medical School, Aristotle University of Thessaloniki, Greece
Abstract

The most frequent enzyme abnormality of the glycolytic pathway which causes hereditary non-spherocytic hemolytic anemia is red cell pyruvate kinase (PK) deficiency. The disease is transmitted as an autosomal recessive trait. The case of a successful pregnancy in a 38 year-old woman with Pyruvate Kinase deficiency along with detection of plasminogen activator inhibitor (PAI-1) 4G/4G homozygous genotype is reported. The pregnancy was uneventful and a healthy girl was born.

Key words: Genetic Counseling, Hematologic and Clotting Problems, Recurrent pregnancy loss
Introduction

The most frequent enzyme abnormality of the glycolytic pathway which causes hereditary non-spherocytic hemolytic anemia is red cell pyruvate kinase (PK) deficiency. Hemolysis varies and can be very serious or milder (1).

Valentine et al (2) first reported this deficiency. Pyruvate kinase catalyzes the conversion of phosphoenolpyruvate and ADP to pyruvate and adenosine trisphosphate (ATP) in the Embden-Meyerhoff glycolytic pathway and provides the major source of energy in the erythrocyte. The enzyme deficiency leads to the accumulation of 2, 3-diphosphoglycerate (DPG) and phosphoenolpyruvate which are the glycolytic pathway intermediates that predispose to increased susceptibility to red cell hemolysis (3). The disease is transmitted as an autosomal
recessive trait, clinical symptoms usually occur in compound heterozygotes for two mutant alleles and in homozygotes. The homozygote carriers require regular transfusions from early childhood while the heterozygotes experience clinical manifestations only under special conditions like infection or pregnancy. PK deficiency has a world-wide distribution. The prevalence of PK deficiency, as assessed by gene frequency studies, has been estimated to be 1:20,000 in the general white population. Recurrent pregnancy losses (RPL) have been connected with gene variants connected to thrombophilia and hypercoagulable state. There is a possible role of the PAI-1 4G\5G gene variant that may be associated to hypofibrinolysis. There are some reports that underline the association between 4G\4G genotype of PAI-1 and recurrent pregnancy loss (RPL) (4, 5) and this association seems to be relevant if thromboembolism (VTE)
is also present (6). The need for more data based on larger population screening is important.

We report the case of a young woman in her second pregnancy suffering from congenital pyruvate kinase deficiency and being homozygous carrier of the polymorphism of PAI-1. She underwent a thrombophilia examination since she already had one miscarriage.

**Case Report**

A 39-year-old woman in her second pregnancy (9th week of gestation) was referred to the Hemoglobinopathy Prevention Unit for genetic counseling as she was diagnosed with pyruvate kinase deficiency from the age of 13. She previously had undergone cholecystectomy, but not splenectomy. The
proposita’s hematological parameters were as follows: Hb: 9.3 g/dL, RBC: 2.45 x10^6/μL, MCV: 114 fL, MCH: 38 pg, RDW: 15.4%, reticulocytes: 15%, ferritin: 730 ng/ml (normal range=20-81). Microscopic examination of peripheral blood smear showed anisocytosis and tear cells. Biochemical analysis of hemoglobin using high-performance liquid chromatography (HPLC) showed normal values for hemoglobin A2 and hemoglobin F. A maternal echo cardiogram was normal, ejection fraction (EF): 75%. We assessed hemoglobin levels every 3 weeks. At 28 weeks of gestation, hemoglobin was 8.3 gr/dl and suffered of palpitations, dyspnea and easy fatigability, so she was transfused with one unit of red cell. The patient also received folic acid 1 mg but did not need iron supplementation due to increased ferritin levels (730ng/ml) due to chronic hemolysis. Fetal growth and well-being were assessed by monthly growth ultra sonography beginning at 20 weeks and weekly biophysical profiles at 32
weeks. The patient was on therapeutic dose of low molecular weight heparin (LMWH), as she was homozygous for 4G/4G allele. This results in 25% higher levels of PAI-1 without being clarified from the literature whether it can lead to thrombosis, miscarriage or pre-eclampsia. After all, pregnancy itself increases the levels of PAI-1. However, due to her first pregnancy loss at 12 weeks of gestation, age and due to her chronic hemolysis, she was put on low molecular heparin (prophylactic dose). During 37 weeks of gestation, the patient had a programmed caesarean delivery. Mother and infant had uncomplicated hospital courses.

**Discussion**

Pyruvate kinase deficiency is inherited in an autosomal recessive manner. More than 130 different mutations at the chromosome 1q21 locus are responsible for the variable clinical severity of
hemolytic. Age at onset of symptoms and severity of anemia are related to the specific mutations mechanism of action and homozygosity compared with compound heterozygosity (7).

The enzymatic deficiency leads to a red cell susceptibility to hypoxic and conformational stress in the spleen and reticuloendothelial system. Definitive diagnosis is made by demonstrating pyruvate kinase deficiency using standardized assays. Patients with Pyruvate Kinase (PK) deficiency are transfusion dependent to varying degrees. An individual’s anemia severity tends to remain constant except in cases related to infection or pregnancy. Splenectomy for individuals requiring frequent transfusion results in a 1–3 g/dL rise in hemoglobin, alleviating hemolysis, and usually avoiding further transfusion. Cholecystectomy is performed for pigment stones or coincidental to splenectomy (7).
Depending on the history of splenectomy, transfusion, and iron overload, echocardiography is indicated as it assesses myocardial hypertrophy secondary to increased cardiac output compensating for chronic anemia (8). In our case, the estimated EF was normal. Folic acid, but not iron supplementation, is indicated. Splenectomy is indicated in very young patients requiring frequent transfusions, in patients who do not tolerate anemia, or in conjunction with cholecystectomy. The patient described did not have a splenectomy as anemia was well tolerated. Indications for red cell transfusion in pregnancy are controversial and unsupported by evidence. Some authors suggest that transfusion should be administered only for symptomatic anemia or in preparation for surgery or pregnancy (9). Patients with pyruvate kinase deficiency have increased red cell 2,3 diphosphoglycerate, decreased hemoglobin oxygen affinity, and increased oxygen release to tissues. Thus, patients
exhibit greater tolerance to increasing oxygen demand than expected on the basis of the hemoglobin. Other authors recommend transfusions to maintain a hemoglobin concentration of 7–8mg/dL or more (10, 11, 12).

Transfusion therapy does not seem to mitigate neonatal outcome. Specifically, while all three reported pregnancies without transfusion (9, 12) resulted in growth-restricted fetuses, so did two of three pregnancies managed with transfusions (11). Pregnant women with pyruvate kinase deficiency should be monitored for hypertensive disorders, observed in three of seven reported cases (10, 12). Finally, it is recommended monthly to perform ultrasonographic assessments of fetal growth after 20 weeks, because 5 of 6 affected pregnancies experienced intrauterine growth restriction.
Recurrent pregnancy loss (RPL) represents a major health problem in up to 5% of women of reproductive age (13). Inherited thrombophilia agents are reported as one of the main causes of RPL especially if several diseases responsible of potential RPL are excluded (an-ovulation, ovarian dysfunction, hypopituitarism and diabetes, uterine malformation, genetic alterations, inflammatory diseases) (14, 15, 16, 17, 18).

Established inherited thrombophilic risk factors include the G1691A mutation of the Factor V (Leiden), the G20210A mutation of the prothrombin gene, and hyperhomocysteinemia. The association between homozygosity for the C677T polymorphism of the methylene-tetra-hydrofolate reductase (MTHFR) gene and the 4G/5G polymorphism of the plasminogen activator inhibitor (PAI-1) gene promoter with thrombosis is controversial. So far, there is no information whether severe pre-
eclampsia is related to these risk factors. Pre-eclampsia and certain variants of the genes coding for angiotensin-converting enzyme, CTLA-4, thrombin, factor V, lipoprotein lipase and plasminogen activator inhibitor-1 are related. As for the rare thrombophilic defects like dysfibrinogenemia, elevated TAFI, elevated PAI-1, t-PA deficiency, only few reported cases exist. The G20210A prothrombin gene mutation and the PAI-1 5G/5G genotype seem to be risk factors inducing pre-eclampsia in women with already existing fetomaternal dysfunction. Among women with G20210A and PAI-1 5G/5G, genotype earlier onset of pre-eclampsia among women is reported (18).

In our case, the patient was diagnosed with PAI-1 polymorphism and 4G/4G homozygous genotype. Taking under consideration age and past medical record, she was treated with LMWH. She was monitored for pre-eclampsia which was not detected.
According to the type of thrombophilia, the patient's additional risk factors and co morbidities, the treatment should be individualized. Women with pyruvate kinase deficiency should be counseled before the pregnancy. They should be informed about the risks of hemolysis and the potential need of blood transfusion. There are few reported cases of pregnancy in women with pyruvate kinase deficiency in the literature. This is the first case reporting pregnancy in a woman with pyruvate kinase deficiency and PAI-1 polymorphism which had a positive outcome both for mother and child.

Disclosure

We declare that all the authors do not have any relationships with companies that may have financial information contained in the manuscript.
References


4. Goodman CS, Coulam CB, Jeyendran RS, Acosta VA, Roussev R. Which thrombophilic gene mutations are risk factors for


